Stable dry powder inhaler formulation of tranilast attenuated antigen-evoked airway inflammation in rats

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 77, Issue 1, 2011, Pages 178-181

  Kawabata, Yohei ^a   Aoki, Yosuke ^a   Matsui, Takuya ^a   Yamamoto, Kiyoshi ^a   Sato, Hideyuki ^a   Onoue, Satomi ^a   Yamada, Shizuo ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Dispersibility; Dry powder inhaler; Solid dispersion; Stability; Tranilast

Indexed keywords

BIOLOGICAL MARKER; CYCLOOXYGENASE 2; EOSINOPHIL PEROXIDASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTATE DEHYDROGENASE; MESSENGER RNA; MYELOPEROXIDASE; NANOCRYSTAL; TRANILAST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTHMA; CONTROLLED STUDY; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; DRY POWDER; GENE EXPRESSION; GRANULOCYTE; LUNG LAVAGE; MALE; NONHUMAN; POWDER INHALER; RAT; RESPIRATORY TRACT INFLAMMATION; ROOM TEMPERATURE;

ADMINISTRATION, INHALATION; ANIMALS; ANTHRANILIC ACIDS; ANTI-ALLERGIC AGENTS; ASTHMA; BIOLOGICAL MARKERS; BRONCHOALVEOLAR LAVAGE FLUID; CYCLOOXYGENASE 2; DRUG COMPOUNDING; DRUG STABILITY; DRY POWDER INHALERS; GRANULOCYTES; INFLAMMATION MEDIATORS; LUNG; MALE; NANOPARTICLES; NF-KAPPA B; OVALBUMIN; POWDERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER;

EID: 78650692763     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2010.11.005     Document Type: Article

References (12)

1. M. Konneh Tranilast Kissei Pharmaceutical IDrugs 1 1998 141 146
2. H. Tamai, O. Katoh, S. Suzuki, K. Fujii, T. Aizawa, S. Takase, H. Kurogane, H. Nishikawa, T. Sone, K. Sakai, and T. Suzuki Impact of tranilast on restenosis after coronary angioplasty: tranilast restenosis following angioplasty trial (TREAT) Am. Heart J. 138 1999 968 975
3. J.L. Rau The inhalation of drugs: advantages and problems Respir. Care 50 2005 367 382
4. Y. Kawabata, K. Yamamoto, K. Debari, S. Onoue, and S. Yamada Novel crystalline solid dispersion of tranilast with high photostability and improved oral bioavailability Eur. J. Pharm. Sci. 39 2010 256 262
5. S. Onoue, Y. Aoki, Y. Kawabata, T. Matsui, K. Yamamoto, H. Sato, Y. Yamauchi, S. Yamada, Development of inhalable nanocrystalline solid dispersion of Tranilast for airway inflammatory diseases, J. Pharm. Sci., in press.
6. S. Misaka, Y. Aoki, S. Karaki, A. Kuwahara, T. Mizumoto, S. Onoue, and S. Yamada Inhalable powder formulation of a stabilized vasoactive intestinal peptide (VIP) derivative: anti-inflammatory effect in experimental asthmatic rats Peptides 31 2010 72 78
7. R.N. Jashnani, P.R. Byron, and R.N. Dalby Testing of dry powder aerosol formulations in different environmental conditions Int. J. Pharm. 113 1995 123 130
8. V. Berard, E. Lesniewska, C. Andres, D. Pertuy, C. Laroche, and Y. Pourcelot Dry powder inhaler: influence of humidity on topology and adhesion studied by AFM Int. J. Pharm. 232 2002 213 224
9. C.C. Winterbourn, M.C. Vissers, and A.J. Kettle Myeloperoxidase Curr. Opin. Hematol. 7 2000 53 58
10. E. Frigas, and G.J. Gleich The eosinophil and the pathophysiology of asthma J. Allergy Clin. Immunol. 77 1986 527 537
11. P.J. Barnes Emerging pharmacotherapies for COPD Chest 134 2008 1278 1286
12. Y. Chen, P. Chen, M. Hanaoka, Y. Droma, and K. Kubo Enhanced levels of prostaglandin E2 and matrix metalloproteinase-2 correlate with the severity of airflow limitation in stable COPD Respirology 13 2008 1014 1021